The immuno-oncology therapy startup has completed a round that included Taiho Pharmaceuticals and AbbVie Ventures.

US-based immuno-oncology drug developer Quentis Therapeutics has closed a $48m series A round featuring pharmaceutical companies AbbVie and Taiho, the former investing through its AbbVie Ventures unit.

Venture capital firm Versant Ventures and investment firm Polaris Partners co-led the round along with LS Polaris Innovation Fund, an affiliate of the latter.

The round also featured Alexandria Venture Investments and New York Ventures, respective investment vehicles for real estate investment trust Alexandria Real Estate Equities and the state of New York’s…